

Supplementary table 1: Example search string from Ovid Medline

Search string	Search team
Free text search	
1	Heart failure.mp.
2	Cardiac failure.mp.
3	Congestive heart failure.mp.
4	Ventric* dysfunction.mp.
5	Cardiac dysfunction.mp.
6	Systolic dysfunction.mp.
7	Cardiac insufficiency.mp.
8	Myocardi* insufficiency.mp.
9	Ventric* insufficiency.mp.
10	Myocardi* dysfunction.mp.
11	Myocardi* failure.mp.
12	Ventric* failure.mp.
13	HF.mp.
14	CHF.mp.
15	CCF.mp.
16	LVSD.mp.
17	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
Medical Subject Heading search	
18	exp Heart failure/ exp Ventricular dysfunction/ or exp
19	Stroke Volume/ or exp Heart diseases

20	18 or 19
Free text search	
21	Advanced.mp.
22	Chronic.mp.
23	Terminal.mp.
24	End stage.mp.
25	Moderate.mp.
26	Severe.mp.
27	Progressive.mp.
28	Persisitent.mp.
29	Fatal.mp.
30	Limiting.mp.
31	Incurable.mp.
32	Unremitting.mp.
33	Decompensated.mp.
34	NYHA class III.mp.
35	NYHA class IV.mp.
36	21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
Free text search	
37	Palliat*.mp.
38	Terminal care.mp.
39	Hospice*.mp.
40	End of life care.mp.
41	Holistic.mp.

- 42 Respite.mp.
- 43 Supportive care.mp.
- 44 Care of the dying.mp.
- 45 Patient centred care.mp.
- 46 Advance* care
- 47 Advance* directive
- 48 37 or 38 or 39 or 40 or 41 or 42 or 43
or 44 or 45 or 46 or 47

Medical Subject Heading search

- 49 exp Palliative care
- 50 exp "Quality of Life"/ or exp Palliative Medicine/ or exp Terminal Care
- 51 exp Hospices/ or exp Hospice Care/
- 52 exp Holistic Health
- 53 exp Home Nursing/ or exp Respite Care/ or Home Care Services/
- 54 exp Patient-Centred Care/
- 55 exp Advance Care planning/
- 56 exp Advance directives/
- 57 49 or 50 or 51 or 52 or 53 or 54 or 55
or 56

Drawing search terms together

- 58 17 or 20
- 59 36 and 58
- 60 48 or 57
- 61 59 and 60

Supplementary table 2: Characteristics of included studies

First author, year and country	Study setting	Participants: sample size (n), age (years), sex (%), disease characteristics (NYHA Class, LVEF)		Intervention and Comparator	Outcomes	Results
		Intervention	Comparator			
Interventional studies						
Aiken LS (20) 2006 USA	Evaluation phase RCT	Note: Mixed population study with subset analysis of CHF patients in some outcome measures.		<u>PhoenixCare</u> Home-based palliative care focused on disease and symptom management, patient and caregiver education on disease management, and social and psychological support.	<ol style="list-style-type: none"> 1. Self-management of illness and knowledge of resources 2. Preparation for end of life 3. Physical and mental functioning <ol style="list-style-type: none"> a. Participation in enjoyable activities b. Symptom control c. Trajectories of mental and 	<ol style="list-style-type: none"> 1. Greater information for self-management, greater appreciation of resources available to help with their illness and initially, better preparedness for daily experiences in the intervention arm. [◇] 2. PhoenixCare participants showed a higher rate of having a living will or advance directive vs controls. (p < 0.05). [◇]
	Community based and Hospital based	N = 100 (patients with CHF = 67)	N = 90 (patients with CHF = 62)			
		Mean Age (SD) = 68 (14)	Mean Age (SD) = 70 (13)			
		Sex: M = 42.0; F = 58.0	Sex: M = 30.0; F = 70.0			

Supplementary table 2: Characteristics of included studies

		No data on NYHA Class or LVEF	No data on NYHA Class or LVEF	<p><u>Usual Care</u></p> <p>Medical and disease orientated care included medication and technical treatment and other support service.</p> <p>Providers: Managed care organisations.</p>	<p>physical functioning</p> <p>4. Utilisation of medical service</p>	<p>3a. NSD in CHF.</p> <p>3b. High symptom distress in PhoenixCare (p < 0.05).</p> <p>3c. NSD in mental and physical functioning among CHF control.</p> <p>4. Relatively unchanged over time with NSD across arms.</p>
<p>Bekelman DB (21) 2015 USA</p>	<p>Evaluation phase RCT with >80% power</p> <p>Community based with outpatient consultations</p>	<p>N = 187</p> <p>Mean Age (SD) = 68.3 (9.6)</p> <p>Sex: M = 95.2; F = 4.8</p> <p>NYHA class I = 16 (8.9%)</p> <p>NYHA class II = 77 (42.8%)</p>	<p>N = 197</p> <p>Mean Age (SD) = 67.9 (10.6)</p> <p>Sex: M = 98.0; F = 2.0</p> <p>NYHA class I = 16 (8.5%)</p> <p>NYHA class II = 85 (45.0%)</p>	<p><u>Patient-Centred Disease Management</u></p> <p>Multidisciplinary collaborative care of HF disease management, screening for and treatment of depression and telemonitoring with patient self-care support.</p> <p>Providers: Registered nurse (co-ordinator), primary care physician, psychiatrist.</p> <p><u>Usual Care</u></p>	<p>1. HF-specific health status</p> <p>2. Depression</p> <p>3. Mortality</p> <p>4. Hospitalisation</p>	<p>1. NSD in KCCQ overall score.</p> <p>2. Greater improvement in PHQ-9 in the intervention arm (p = 0.01).</p> <p>3. Fewer patients died in the intervention arm (p = 0.04).</p> <p>4. NSD in hospitalisations.</p>

Supplementary table 2: Characteristics of included studies

		<p>NYHA class III = 82 (45.6%)</p> <p>NYHA class IV = 5 (2.8%)</p> <p>LVEF: Normal = 78 (45.6%) Mild = 34 (19.9%) Moderate = 46 (26.9%) Severe = 13 (7.6%)</p>	<p>NYHA class III = 82 (43.4%)</p> <p>NYHA class IV = 6 (3.2%)</p> <p>LVEF: Normal = 84 (47.5%) Mild = 34 (19.2%) Moderate = 32 (18.1%) Severe = 27 (15.3%)</p>	<p>Regular care at the discretion of health care provider. Information sheets for self-care given and if patients screened positive for depression at baseline, primary care physicians were notified.</p> <p>Providers: Regular health care professionals and nurses.</p>		
<p>Brännström M (22) 2014 Sweden</p>	<p>Evaluation phase RCT with 80% power</p> <p>Community based with outpatient consultations</p>	<p>N = 36</p> <p>Mean Age (SD) = 81.9 (7.2)</p> <p>Sex: M = 72.2; F = 27.8</p>	<p>N = 36</p> <p>Mean Age (SD) = 76.6 (10.2)</p> <p>Sex: M = 69.4; F = 30.6</p>	<p><u>Palliative advanced home care and heart failure care (PREFER) model</u></p> <p>Person-centred care, total care including assessment of symptoms, quality of life, and risk, and registration into HF and palliative care registry.</p>	<ol style="list-style-type: none"> Symptom burden Health related quality of life Disease-specific quality of life Functional classes Hospitalisation Resource utilisation 	<ol style="list-style-type: none"> NSD in overall score Age-adjusted health related quality of life was better in PREFER group (p = 0.02). NSD in overall disease specific quality of life. Improved mean NYHA class (p = 0.012) and

Supplementary table 2: Characteristics of included studies

		<p>NYHA class III = 28 (77.8%)</p> <p>NYHA class IV = 8 (22.2%)</p> <p>LVEF: 40-49% = 13 (36.1%) 30-39% = 16 (44.4%) <30% = 7 (19.4%)</p>	<p>NYHA class III = 23 (63.9%)</p> <p>NYHA class IV = 11 (30.6%)</p> <p>LVEF: 40-49% = 12 (33.3%) 30-39% = 21 (58.3%) <30% = 3 (8.3%)</p>	<p>Providers: Specialised nurses, palliative care nurses, cardiologist, palliative care physician, physiotherapist, and occupational therapist.</p> <p><u>Usual care</u> No information.</p> <p>Providers: General practitioners or doctors and/ or the nurse-led heart failure clinic.</p>		<p>more experienced</p> <p>improved NYHA class (p = 0.015) in the PREFER arm.</p> <p>5. Fewer hospitalisations in the PREFER group (p = 0.009); with fewer days spent in hospital (p = 0.0011); NSD in mortality</p> <p>6. Utilisation of visits differed significantly between the two arms in favour of the intervention, but precise results are unclear.</p>
<p>Hopp FP (23) 2016 USA</p>	<p>Evaluation phase RCT with approx. 80% power</p> <p>Hospital based</p>	<p>N = 43</p> <p>Mean Age (SD) = 67.0 (11.0)</p>	<p>N = 42</p> <p>Mean Age (SD) = 68.0 (13.0)</p>	<p><u>Palliative Care Consultation</u></p> <p>Clinical interviews to assess for uncontrolled symptoms, goals of care, advance care planning, code status, and desired post-treatment residential setting.</p>	<p>1. Election vs non-election of comfort care</p> <p>a. Outpatient hospice</p> <p>b. Inpatient hospice</p>	<p>1. NSD in the primary end point.</p> <p>2. NSD in mortality.</p>

Supplementary table 2: Characteristics of included studies

		Sex: M = 60.5; F = 39.5	Sex: M = 42.9; F = 57.1	Providers: Physician and advanced nurse practitioner. Other professionals participated as needed – chaplains and social workers.	c. A "Do Not Resuscitate" order during hospitalisation	
		No data on NYHA Class	No data on NYHA Class		d. A "Do Not Resuscitate" order at home or nursing home	
		Mean LVEF = 36.4% (16.7)	Mean LVEF = 38.1% (16.8)	<u>Usual Care</u> No information.		
Rogers JG (24) 2017 USA	Evaluation phase RCT with <80% power Community based and Hospital based	N = 75 Mean Age (SD) = 71.9 (12.4) Sex: M = 56.0; F = 44.0 NYHA class III = 54 (72.0%) NYHA class IV = 15 (20.0%) LVEF:	N = 75 Mean Age (SD) = 69.8 (13.4) Sex: M = 49.3; F = 50.7 NYHA class III = 58 (77.3%) NYHA class IV = 5 (6.7%) LVEF:	<u>Palliative Care in Heart Failure (PAL-HF)</u> Interdisciplinary, guideline-driven, multicomponent palliative care intervention in combination with contemporary HF management, including assessment and management of physical symptoms, psychosocial and spiritual concerns and advance care planning	1. HF-specific quality of life 2. General and palliative care specific, health related quality of life 3. Spiritual wellbeing 4. Depression and anxiety	1. Greater improvements in the HF-specific quality of life (p = 0.03) in PAL-HF arm 2. Greater improvement in health related quality of life in the intervention arm (p = 0.035). 3. Spiritual wellbeing was better improved in the intervention arm (p = 0.027) 4. Depressive symptoms improved more in the

Supplementary table 2: Characteristics of included studies

		<p>>55% = 21 (28.0%)</p> <p>40-55% = 14 (18.7%)</p> <p>25-40% = 17 (22.7%)</p> <p><25 = 23 (30.7%)</p>	<p>>55% = 14 (18.7%)</p> <p>40-55% = 19 (25.3%)</p> <p>25-40% = 14 (18.7%)</p> <p><25 = 28 (37.3%)</p>	<p>Providers: Palliative care nurse practitioner, palliative medicine board-certified physician, clinical cardiology team, and when required, mental health provider.</p> <p><u>Usual care</u></p> <p>Inpatient care focused on symptom relief with outpatient follow up. They were not denied access to inpatient palliative care consultation.</p> <p>Providers: Cardiologist directed team with HF expertise in inpatient setting. General practitioners , HF cardiologists, nurse practitioners in outpatient setting.</p>		<p>intervention arm (p = 0.02), as well as anxiety (p = 0.048).</p>
<p>Sahlen KG (25) 2015 Sweden</p>	<p>Evaluation phase RCT with 80% power</p>	<p>N = 36</p> <p>Mean Age (SD) = 81.9 (7.2)</p>	<p>N = 36</p> <p>Mean Age (SD) = 76.6 (10.2)</p>	<p>Note: Same study as Brännström <i>et al.</i> (3)</p> <p><u>PREFER model</u></p>	<p>1. Quality adjusted life years</p> <p>2. Costs of care</p>	<p>1. Small but significant difference in the weight of the quality adjusted life year (p = 0.026) favouring PREFER.</p>

Supplementary table 2: Characteristics of included studies

	Community based with outpatient consultations	Sex: M = 72.2; F = 27.8 No data on NYHA Class or LVEF	Sex: M = 69.4; F = 30.6 No data on NYHA Class or LVEF	<p>Person-centred care, total care including assessment of symptoms, quality of life, and risk, and registration into HF and palliative care registry.</p> <p>Providers: Specialised nurses, palliative care nurses, cardiologist, palliative care physician, physiotherapist, and occupational therapist.</p> <p><u>Usual care</u> No information.</p> <p>Providers: General practitioners or doctors and/ or the nurse-led heart failure clinic.</p>		2. NSD in cost of care between the two arms.
Sidebottom AC (26) 2015 USA	Evaluation phase RCT, but poor recruitment	N = 116 Mean Age (SD) = 76.0 (11.9)	N = 116 Mean Age (SD) = 70.9 (13.6)	<p><u>Palliative care</u> Assessment of symptom burden, emotional, spiritual and psychosocial care, coordination of care orders, recommendation for</p>	<ol style="list-style-type: none"> 1. Symptom burden 2. Depression 3. Quality of life 4. Readmissions 5. Hospice use 	1. Difference in symptom burden favours intervention in mean change from baseline (p < 0.001).

Supplementary table 2: Characteristics of included studies

	<p>resulted in 47.5% power</p> <p>1 Inpatient consultation</p>	<p>Sex: M = 47.4; F = 52.6</p> <p>No data on NYHA Class or LVEF</p>	<p>Sex: M = 57.8; F = 42.2</p> <p>No data on NYHA Class or LVEF</p>	<p>change in current or future treatments.</p> <p>Providers: 4 physicians board certified in hospice and palliative medicine, 2 clinical nurse specialists board certified in advanced practice palliative care nursing, a social worker and a chaplain.</p> <p><u>Control group</u> No information.</p>	<p>6. ACP</p> <p>7. Mortality</p>	<p>2. Difference in depression favours intervention (p < 0.001).</p> <p>3. Improvement of quality of life is better in the intervention arm (p < 0.001).</p> <p>4. NSD in readmissions</p> <p>5. NSD in hospice use between arms.</p> <p>6. ACP process 2.87 times more likely in intervention.</p> <p>7. NSD in mortality.</p>
<p>Wong FKY (27) 2016 China</p>	<p>Evaluation phase RCT</p> <p>Community based</p>	<p>N = 43</p> <p>Mean Age (SD) = 78.3 (16.8)</p> <p>Sex: M = 43.9; F = 56.1</p>	<p>N = 41</p> <p>Mean Age (SD) = 78.4 (10.0)</p> <p>Sex: M = 61.0; F = 39.0</p>	<p><u>Transitional Care Palliative End-Stage Heart Failure</u></p> <p>Pre-discharge assessment, patients' needs assessment (environmental, psychosocial, physiological and health-related behaviour) and intervention, goal setting and creating a mutually agree care plan.</p>	<p>1. Readmissions at 4 and 12 weeks</p> <p>2. Symptom intensity</p> <p>3. Functional status</p> <p>4. Quality of life</p> <p>5. Satisfaction with care</p>	<p>1. NSD in 4 week re-admission rate, however there was significantly fewer 12 week re-admissions in the intervention arm (p = 0.001).</p>

Supplementary table 2: Characteristics of included studies

		<p>NYHA class II = 6 (14.0%)</p> <p>NYHA class III = 31 (72.0%)</p> <p>NYHA class IV = 6 (14.0%)</p> <p>Mean LVEF = 39.0% (14.0)</p>	<p>NYHA class II = 3 (7.3%)</p> <p>NYHA class III = 22 (53.7%)</p> <p>NYHA class IV = 16 (39.0 %)</p> <p>Mean LVEF = 37.0% (17.0)</p>	<p>Providers: Nurse case managers (primary provider), trained volunteers, and nursing students.</p> <p><u>Control group</u> Usual care – palliative care medical clinic, discharge advice on symptom management and medication, and referrals if appropriate. Also, control group received 2 attention control social calls.</p>		<ol style="list-style-type: none"> 2. NSD in symptom burden across groups. 3. NSD in functional status between or within groups. 4. Both heart failure specific (p = 0.01) and palliative care specific (p = 0.05) quality of life tools found significant improvement in the intervention arm. 5. The intervention group had significantly (p < 0.001) higher satisfaction with care.
<p>Paes P (28)</p> <p>2005</p> <p>UK</p>	<p>Feasibility and pilot phase RCT</p> <p>Outpatient consultations</p>	<p>N = 6</p> <p>Mean Age (SD) = 73.2 (4.2)</p>	<p>N = 7</p> <p>Mean Age (SD) = 78.0 (7.0)</p>	<p><u>Palliative care consultation</u></p> <p>1 hour of palliative care medical outpatient consultation, followed by monthly 30-minute consultation for a total of 5 months.</p>	<ol style="list-style-type: none"> 1. Depression 2. Quality of life 3. Clinical evaluation 	<ol style="list-style-type: none"> 1. NSD in depression between treatment arms. 2. NSD in quality of life between treatment arms.

Supplementary table 2: Characteristics of included studies

		Sex: M = 100.0; F = 0.0 NYHA class III = 3 (50.0%) NYHA class IV = 3 (50%) No data on LVEF	Sex: M = 80.0; F = 20.0 NYHA class III = 3 (60.0%) NYHA class IV = 2 (40%) No data on LVEF	Provider: Palliative care physician. <u>Control group</u> Regular cardiology care.		3. The evaluation forms were positive and found the format acceptable.
O'Donnell A (30) 2018 USA	Pilot study RCT In-patient or community consultations	N = 26 Mean Age (SD) = 74.7 (11.2) Sex: M 53.9, F = 46.1 NYHA class 1 or 2 = 10 (38.5%)	N = 24 Mean Age (SD) = 69.2 (10.2) Sex: M = 62.5, F = 37.5	<u>Social Work (palliative care trained) consultation</u> <u>Conversation about goals of care and advanced care planning started in hospital and continued in the community post-discharge.</u> <u>Palliative physician assessment and management plan including outpatient palliative medicine consults as needed</u> <u>Provider: Palliative social worker and palliative physician</u>	1. % patients with ACP documentation and % aligned preferences at 6 months 2. FACIT-Sp 3. Patient and provider preferences of care questionnaire 4. KCCQ-12 5. EQ-5D VAS 6. PHQ-8 7. GAD-7	1. Higher % with ACP documentation in intervention arm (p = 0.02), and better alignment with physician assessed prognosis in intervention arm (p <0.001) NSD in any other outcome measure.

Supplementary table 2: Characteristics of included studies

		<p>NYHA class 3 or 4 = 16 (61.5%)</p> <p>Mean LVEF = 30% (14)</p>	<p>NYHA class 1 or 2 = 8 (33.3%)</p> <p>NYHA class 3 or 4 = 16 (66.7%)</p> <p>Mean LVEF = 36% (17)</p>	<p><u>Control: Usual care, includes available information about palliative care and advance care planning, and access to in-patient palliative care team if needed. NB. Out patient palliative care consults NOT part of usual care.</u></p>		
<p>Johnson MJ (31) 2018 UK</p>	<p>Out-patient or home-based interventions</p>	<p>Cohort 1: palliative cardiology</p> <p>N = 43</p> <p>Mean Age (SD) = 75.8 (12.3)</p> <p>Sex: M 55.8, F = 44.2</p>	<p>Cohort 2: usual care</p> <p>N = 34</p> <p>Mean Age (SD) = 78.4 (11.3)</p> <p>Sex: M 50.0, F = 50.0</p> <p>NYHA: class I = 0</p>	<p><u>Cohort 1. Palliative cardiology clinic consultations with a cardiologist and heart failure nurse consultant with a special interest in palliative care. Full holistic assessment, medication review, advance care planning, symptom management, care co-ordination, and community based follow up with liaison with primary care. Referrals to other services including specialist palliative care as needed</u></p>	<ol style="list-style-type: none"> 1. Feasibility measures (recruitment, attrition, data quality, sample size calculation for trial) 2. AKPS 3. ESAS 4. KCCQ-12 5. HADs 6. EQ-5L-5D 7. Health service utilisation 	<p>Groups imbalanced; Cohort 1 less well, more symptomatic and worse QoL</p> <ol style="list-style-type: none"> 1. Concluded a future trial was feasibility and sample size for KCCQ-12 as primary outcome calculated 2. NSD AKPS 3. Greater improvement in usual care (p = 0.046) 4. NSD KCCQ-12

Supplementary table 2: Characteristics of included studies

		<p>NYHA: class I = 0</p> <p>class II = 0</p> <p>class III = 40 (93.0)</p> <p>class IV = 3 (7.0)</p>	<p>class II = 3 (8.8)</p> <p>class III = 30 (88.2)</p> <p>class IV = 1 (2.9)</p>	<p><u>Cohort 2. Usual care. Case-based care from heart failure nurse specialist in community care, with access to hospital-based cardiology physicians as needed. Specialist palliative care available if referred.</u></p>	<p>8. Patient understanding</p> <p>9. ACP documentation</p> <p>10. Survival</p>	<p>5. NSD HADs</p> <p>6. NSD EQ-5D-5L</p> <p>7. Fewer nights in hospital but more GP visits in cohort 1. Average costs reduced by £785 per patient.</p> <p>8. Better patient understanding in Cohort 1 (p<0.001)</p> <p>9. More ACP documentation in Cohort 1 (p<0.001)</p> <p>10. NSD in survival</p>
<p>Bakitas M (29) 2017 USA</p>	<p>Single-arm feasibility and pilot phase trial</p> <p>Community based with outpatient consultations</p>	<p>N = 61</p> <p>Mean Age (SD) = 70.59 (10.7)</p> <p>Sex: M = 50.8; F = 49.2</p> <p>NYHA class I = 1 (1.6%)</p> <p>NYHA class II = 3 (4.9%)</p> <p>NYHA class III = 43 (70.5%)</p>	<p><u>Educate, Nurture, Advise, Before Life Ends Comprehensive Heartcare for Patients and Caregivers (ENABLE CHF-PC)</u></p> <p>A telephonic early palliative care intervention for rural-dwelling, underserved HF patient and caregivers including in-person palliative care consultation, weekly</p>	<p>1. Feasibility and acceptability</p> <p>2. Patient reported outcomes</p> <p>a. Disease specific quality of life</p> <p>b. Symptom burden</p>	<p>1. Results discussed in paper – not relevant to the review.</p> <p>2. Patient reported outcomes</p> <p>a. Significant improvement in KCCQ clinical</p>	

Supplementary table 2: Characteristics of included studies

		<p>NYHA class IV = 12 (19.7%) Unknown = 2 (3.3%) Mean LVEF = 37.86% (16.3)</p>	<p>semi-structured telephone palliative care nurse coaching, and monthly follow-ups. Providers: Trained nurse coaches</p>	<p>c. Anxiety and depression d. General wellbeing e. Assessment of chronic illness care 3. Caregiver reported outcomes a. Caregiving outcomes measuring life changes b. Anxiety and depression c. General wellbeing d. Caregiver burden e. Positive aspects of caregiving 4. Resource use</p>	<p>summary (p = 0.009) b. Significant reduction in symptom burden (p = 0.0004) c. NSD in anxiety or depression d. NSD in physical health, however there was significant improvement in the global mental health T score of PROMIS (p = 0.04) e. NSD in PACIC summary score. 3. Caregiver reported outcomes a. NSD in caregiving outcomes.</p>
--	--	---	---	--	---

Supplementary table 2: Characteristics of included studies

				<ul style="list-style-type: none"> a. Number of days in hospital per month b. Number of days in ICU per month c. Number of visits to ED per month d. Hospice use 	<ul style="list-style-type: none"> b. NSD in anxiety or depression. c. NSD in the carer's general wellbeing. d. Significant reduction in burden on the carer (p = 0.002) e. NSD in the positive aspects of caregiving. <p>4. Resource use</p> <ul style="list-style-type: none"> a. Significant reduction in number of days in hospital per month (p = 0.002) b. NSD in number of days in ICU per month c. NSD in number of visits to ED per month
--	--	--	--	--	---

Supplementary table 2: Characteristics of included studies

						d. NSD in hospice use.
Tadwalkar R (32) 2014 USA	Quasi-experimental trial Inpatient visits	N = 14 Mean Age (SD) = 58 (11) Sex: M = 42.9; F = 57.1 No data on NYHA Class or LVEF	N = 9 Mean Age (SD) = 57 (10) Sex: M = 55.6; F = 44.4 No data on NYHA Class or LVEF	<u>Religious support</u> Prayer, reading of religious text, religion-specific rituals, and other pastoral care. Provider: member of the chaplaincy. <u>Non-religious support</u> Personal discussions, recreational activities, undertaking social and spiritual support. Provider: in-house volunteer.	1. Depression 2. Spirituality 3. Symptom burden 4. Enjoyment and life satisfaction	1. Significant reduction in depression over time but there was NSD between the two groups. 2. NSD in spirituality between the two groups or over time. 3. NSD in symptom burden between groups or over time. 4. NSD in enjoyment and life satisfaction between groups or over time.
Observational studies						
Connor SR (33) 2007	Retrospective Cohort Study Hospice care	N = 2095 (patients with CHF = 83)	N = 2260 (patients with CHF = 457)	<u>Intervention</u> Hospice care <u>Comparator</u>	1. Survival	1. Increase in survival period in those who received hospice care (p = 0.0540).

Supplementary table 2: Characteristics of included studies

<p>USA</p>		<p>Mean Age = 73.5</p> <p>Sex: M = 55; F = 45</p> <p>No data on NYHA Class or LVEF</p>	<p>Mean Age = 73.9</p> <p>Sex: M = 59; F = 41</p> <p>No data on NYHA Class or LVEF</p>	<p>No claims for hospice care</p>		
<p>Enguidanos SM (34) 2005 USA</p>	<p>Prospective Cohort Study</p> <p>Community based with outpatient consultations</p>	<p>Note: Mixed population study with subset analysis of CHF patients</p> <p>N = 159 (patients with CHF = 31)</p> <p>Mean Age (SD) = 70 (13.92)</p> <p>Sex: M = 49.1; F = 50.9</p>	<p>N = 139 (patients with CHF = 51)</p> <p>Mean Age (SD) = 73 (13.29)</p> <p>Sex: M = 44.6; F = 55.4</p>	<p><u>Kaiser Permanente Home-based Palliative Care Program</u></p> <p>Extensive patient and family education on the disease/ condition; training in symptom control; psychosocial support aimed at assisting in making care choices in advance.</p> <p>Providers: Physicians, nurses, social workers, and other health care professionals.</p> <p><u>Usual Care</u></p>	<p>1. Severity of illness</p> <p>2. Service use</p> <p>3. Site of death</p> <p>4. Days on service</p> <p>5. Costs of care</p>	<p>1. Intervention group had significantly (p < 0.001) more severe illness at enrolment. ◇</p> <p>2. NSD in obtaining hospice care between groups. ◇</p> <p>3. Palliative care arm were significantly more likely to die at home (p < 0.001).</p> <p>4. Significantly fewer days on service (p <</p>

Supplementary table 2: Characteristics of included studies

		No data on NYHA Class or LVEF	No data on NYHA Class or LVEF	Standard Kaiser Permanente TriCentral Service Area care. Standard health care in response to needs and home care only when Medicare certified criteria are fulfilled. Access to psychosocial support and social services is very limited.		0.001) in the intervention arm. 5. Palliative care group on average cost less than those in the control group.
Pattenden JF (35) 2013 UK	Prospective Cohort Study Community based	N = 99 Mean Age (SD) = 81.7 Sex: M = 60.6; F = 39.4 No data on NYHA Class or LVEF	N = 98 Mean Age (SD) = 78.85 Sex: M = 62.0; F = 37.8 No data on NYHA Class or LVEF	<u>Better Together Intervention</u> Self-management education and advice to patients and their carers, clinical assessment and regular monitoring and review, palliative nursing e.g. medication for symptoms and psychological support, respite care. Providers: British Heart Failure (BHF) Heart Failure Specialist Nurses (HFSN); Marie Curie Cancer Care Nurses (MCN), Marie Curie Cancer Care Healthcare	1. Resource use – admissions, length of stay 2. Costs of care 3. Benefits of care – death in preferred place of care 4. Cost-effectiveness	1. Smaller proportion of patients in the intervention group in Bradford was admitted to hospital ($p < 0.01$), and fewer admissions per patient in the intervention arm in Poole ($p < 0.05$). NSD in LOS. 2. Fewer costs of care in the intervention in both sites (significant in Bradford).

Supplementary table 2: Characteristics of included studies

				<p>Assistants (MCHCAs); district nurses and other support services.</p> <p><u>Control patients</u> 'Convenience sample' historical sample.</p>		<ol style="list-style-type: none"> 3. Significantly different distribution of place of death ($p < 0.0001$). 4. Uncertainty around incremental cost-effectiveness.
<p>Evangelista LS† (36) 2014 USA</p>	<p>Prospective Single-arm Cohort Study</p> <p>Outpatient consultations</p>	<p>N = 29</p> <p>Mean Age (SD) = 53.3 (7.3)</p> <p>Sex: M = 75.9; F = 24.1</p> <p>NYHA class II = 20 (69.0%) NYHA class III = 9 (31.0%)</p> <p>Mean LVEF = 23.1% (4.3)</p>	<p>N = 13</p> <p>Mean Age (SD) = 52.5 (7.6)</p> <p>Sex: M = 61.5; F = 38.5</p> <p>NYHA class II = 9 (69.2%) NYHA class III = 4 (30.8%)</p> <p>Mean LVEF = 30.5% (9.7)</p>	<p><u>Palliative Care</u></p> <p>Intake summary with current health status and treatment regimen, assessment of physical and psychological symptoms, determine illness understanding, establish goals of care, assist with treatment decision making and coordination of care.</p> <p>Providers: Palliative care specialist (e.g. physician or advance practice nurse).</p> <p><u>'Intervention group'</u></p>	<ol style="list-style-type: none"> 1. Perceived control 2. Patient activation 3. Symptom distress 	<ol style="list-style-type: none"> 1. Greater improvement in perceived control ($p < 0.001$). 2. Greater improvement in activation ($p < 0.001$). 3. Greater reduction in symptom distress ($p < 0.001$).

Supplementary table 2: Characteristics of included studies

				<p>Participants receiving > 2 palliative care consultations.</p> <p><u>'Comparator group'</u> Participants receiving ≤ 1 palliative care consultations.</p>		
<p>Evangelista LS* (37) 2014 USA</p>	<p>Prospective Single-arm Cohort Study</p> <p>Outpatient consultations</p>	<p>N = 29</p> <p>Mean Age (SD) = 54.1 (8.4)</p> <p>Sex: M = 75.9; F = 24.1</p> <p>NYHA class II = 20 (69.0%) NYHA class III = 9 (31.0%)</p> <p>Mean LVEF = 25.9% (5.3)</p>	<p>N = 7</p> <p>Mean Age (SD) = 52.7 (6.3)</p> <p>Sex: M = 57.1; F = 42.9</p> <p>NYHA class II = 5 (71.4%) NYHA class III = 2 (28.6%)</p> <p>Mean LVEF = 23.1% (4.3)</p>	<p><u>Palliative Care</u></p> <p>Comprehensive physical and psychosocial assessment, discussions about advance care planning, developed a treatment plan (with participants) and listing goals of care.</p> <p>Providers: Palliative care specialist (e.g. physician or advance practice nurse).</p> <p><u>'Intervention group'</u> Participants receiving palliative care consultation and follow up.</p> <p><u>'Comparator group'</u></p>	<p>1. Symptom rating</p> <p>2. Type of palliative care, focus of care, medication use</p>	<p>1. Improvement in symptom burden in those who were followed up (p < 0.001).</p> <p>2. Patients who chose to have additional palliative care input were referred to:</p> <ul style="list-style-type: none"> Pharmacist for new medication (69%) or changes to their medication (24%) social work support (69%)

Supplementary table 2: Characteristics of included studies

				Participants receiving initial palliative care consultation only.		<ul style="list-style-type: none"> • physical and occupational therapists (66%) • psychiatrists (55%) • chaplain (45%) • home health (83%) • support groups (31%) and • hospice (7%).
Taylor GJ (38) 2017 USA	Retrospective Single-arm Cohort Study Community based	<p>N = 32</p> <p>Age Range (Median) = 48-94 (70)</p> <p>Sex: M = 100; F = 0</p> <p>NYHA class III = 2 (6.7%)</p> <p>NYHA class IV = 28 (93.3%)</p> <p>No specific data on LVEF, but 23 patients had HFrEF (LVEF <30%) and 7 had HFpEF.</p>	<p><u>Intervention</u></p> <p>Home-delivered palliative care with intensive guidelines-directed medical therapy using the standard hospice approach to psychosocial and spiritual aspects of end-of-life care, optimising the drug therapy, and laboratory evaluation when clinically indicated.</p> <p>Providers: Home-hospice nurses, cardiologists, social workers, chaplains, and volunteers.</p>	<ol style="list-style-type: none"> 1. Re-hospitalisations 2. Death at home 3. NYHA functional class 4. BNP levels 	<ol style="list-style-type: none"> 1. Drop in hospital admissions from 110 admissions in the 6 months prior to enrolment to 26 admissions after enrolment. 2. 18 out of the 21 patients who died, did so at home. 3. Improvement in pre-post NYHA class IV 	

Supplementary table 2: Characteristics of included studies

				No control		versus NYHA class III (p < 0.001). 4. Improvement in BNP levels following treatment with L-dopa (p = 0.014).
Wong RC (39) 2013 Singapore	Prospective Single-arm Cohort Study Community based	N = 44 Mean Age (SD) = 79 (9) Sex: M = 38.6; F = 61.4 NYHA class III = 31 (70.0%) NYHA class IV = 13 (30.0%) No data on LVEF		<u>Home Palliative Care Program</u> Measure patient's physiological parameters, physical examination to elicit relevant signs and symptoms, medication modification or initiation to palliate patient's symptoms. Providers: Doctor, nurse and/ or counsellor. No control	1. HF hospitalisation 2. All cause hospitalisation 3. Time to death	1. Mean HF hospitalisation improved from baseline (p < 0.0001). 2. Mean all-cause hospitalisation improved from baseline (p < 0.0001). 3. Mean time to death was 5.5 months.
Cassel JB (40) 2016	Retrospective Case-Control Study	N = 174 Mean Age (SD) = 87.5 (6.6)	N = 499 Mean Age (SD) = 87.1 (6.4)	<u>Transitions</u> Concurrent care home-based program including in home medical consultation, ongoing	1. Costs: a. Costs per month for hospital care	1. Improvement in costs per month for hospital care (p < 0.001) and all costs per month (p <

Supplementary table 2: Characteristics of included studies

<p>USA</p>	<p>Community based</p>	<p>Sex: M = 44.3; F = 55.7</p> <p>No data on NYHA Class or LVEF</p>	<p>Sex: M = 43.7; F = 56.3</p> <p>No data on NYHA Class or LVEF</p>	<p>prognostication, caregiver support, advance healthcare planning, symptom management, education, and psychosocial and spiritual support.</p> <p>Providers: Doctors, nurses, spiritual care providers, and social workers.</p> <p><u>Comparator</u> No information.</p>	<p>b. Costs per month for other care</p> <p>c. All costs per month</p> <p>2. Hospitalisation</p> <p>a. Percentage hospitalised at least once</p> <p>b. Number of hospitalisations per month</p> <p>c. Number of hospital days per month</p> <p>d. 30-day readmission rate</p> <p>e. ICU stay during admission within 30 days of death</p> <p>3. Admission within 30 days of death and death in hospital</p>	<p>0.001) in the Transitions participants. NSD in costs per month for other care.</p> <p>2. Lower percentage of patients hospitalised at least once, fewer number of hospitalisations per month, fewer number of hospital days per month, lower rate of 30-day readmission and lower rate of ICU stay prior to death (p < 0.001) in the intervention arm.</p> <p>3. Lower percentage of patients from the Transitions arm were admitted within 30 days of death and dying in hospital (P <0.001)</p>
-------------------	------------------------	---	---	--	---	--

Supplementary table 2: Characteristics of included studies

<p>Evangelista LS (41) 2012 USA</p>	<p>Prospective Case-Control Study 1 Outpatient consultation</p>	<p>N = 36 Mean Age (SD) = 53.9 (8.0) Sex: M = 72.2; F = 27.8 NYHA class II = 25 (69.4%) NYHA class III = 11 (30.6%) Mean LVEF = 25.4% (5.2)</p>	<p>N = 36 Mean Age (SD) = 53.3 (8.7) Sex: M = 69.4; F = 30.6 NYHA class II = 26 (72.2%) NYHA class III = 10 (27.8%) Mean LVEF = 26.0% (6.2)</p>	<p><u>Palliative care consultation</u> Assessment of current medical status and screening intake, evaluation of patient's goals and preferences, assessment of areas of perceived needs and establish a treatment plan with co-ordination of care. Providers: Palliative care physician or advance practice nurse. <u>Control</u> No information.</p>	<p>1. Symptom burden 2. Depression 3. Quality of life</p>	<p>1. Lower symptom burden following intervention (p = 0.031). 2. Lower depression following intervention (p = 0.034). 3. Quality of life significantly improved following intervention (p = 0.015).</p>
<p>Blecker S (42) 2011 USA</p>	<p>Cross- Sectional Study Hospice Care</p>	<p>N = 6,436 Mean Age (SD) = 85.0 (7.6) Sex: M = 39.5; F = 60.5</p>	<p>N = 10,177 Mean Age (SD) = 83.6 (7.9) Sex: M = 44.5; F = 55.5</p>	<p><u>Intervention</u> Hospice care <u>Comparator</u> No claims for hospice care</p>	<p>1. Costs 2. Resource use – hospitalisations, ICU admission, length of stay in hospital and ICU</p>	<p>1. Higher total adjusted expenditures in hospice care. 2. Hospice care patients were less likely to be admitted to hospital or have ICU stay during this time, and spent</p>

Supplementary table 2: Characteristics of included studies

		No data on NYHA Class or LVEF	No data on NYHA Class or LVEF			significantly less time in hospital or ICU.
--	--	-------------------------------------	-------------------------------------	--	--	--

Note: Evangelista LS 2014† is titled: On-going palliative care enhances perceived control and patient activation and reduces symptom distress in patients with symptomatic heart failure: A pilot study and Evangelista LS 2014 is titled: Does the Type and Frequency of Palliative Care Services Received by Patients with Advanced Heart Failure Impact Symptom Burden?*

◇ is used where there is no subset analysis of CHF population in mixed population studies.

Abbreviations: NYHA = New York Heart Association; LVEF = Left Ventricular Ejection Fraction; RCT = Randomised Controlled Trial; CHF = Congestive Heart Failure; SD = Standard Deviation; HF = Heart Failure; KCCQ = Kansas City Cardiomyopathy Questionnaire; PHQ-9 = Patient Health Questionnaire-9; ACP = Advance Care Planning; NSD = no significant difference; LOS = length of stay.

Supplementary table 3: Breakdown of palliative care components delivered in the included studies

Study	Components of palliative care	Assessment of current status	Assessment of need	Assessment of quality of life	Symptom management	Psychological support	Social support	Spiritual support	Medication review and monitoring	Tele-health and monitoring	Patient education	Goal setting	Advance care planning	Coordination of care	Multidisciplinary involvement	Carer/family support
Aiken LS (20)		✓	✓		✓	✓	✓		✓		✓		✓	✓	✓	✓
Bekelman DB (21)		✓	✓	✓	✓	✓			✓	✓	✓				✓	
Brännström M (22)		✓	✓	✓	✓					✓	✓	✓	✓	✓	✓	✓
Hopp FP (23)			✓									✓	✓		✓	
Rogers JG (24)		✓	✓	✓	✓	✓	✓	✓	✓			✓		✓	✓	
Sahlen KG (25)		✓	✓	✓	✓					✓	✓	✓	✓	✓	✓	✓
Sidebottom AC (26)		✓	✓	✓	✓	✓	✓	✓	✓				✓	✓	✓	
Wong FKY (27)		✓	✓	✓	✓					✓		✓	✓		✓	
Paes P (28)		✓	✓	✓	✓	✓			✓		✓		✓		✓	
Bakitas M (29)		✓	✓	✓	✓					✓	✓	✓			✓	✓
O'Donnell A (30)		✓	✓	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓	✓
Johnson MJ (31)		✓	✓	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓	✓
Tadwalkar R (32)			✓	✓		✓		✓							✓	
Connor SR (33)		NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Enguidanos SM (34)		✓	✓		✓	✓	✓	✓				✓	✓	✓	✓	
Pattenden JF (35)		✓	✓		✓	✓			✓		✓				✓	✓
Evangelista LS[†] (36)		✓	✓		✓	✓				✓	✓	✓	✓	✓	✓	
Evangelista LS[*] (37)		✓	✓		✓	✓	✓	✓	✓			✓	✓	✓	✓	
Taylor GJ (38)		✓	✓		✓	✓	✓	✓	✓	✓			✓	✓	✓	
Wong RC (39)		✓	✓		✓				✓	✓			✓		✓	
Cassel JB (40)		✓	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓	✓	✓
Evangelista LS (41)		✓	✓	✓	✓	✓	✓		✓		✓	✓	✓		✓	
Blecker S (42)		NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

Supplementary table 4: Results of risk of bias assessment with the Cochrane Risk of Bias tool

Study	Adequate sequence generation?	Allocation concealment?	Blinding (participants and personnel)	Blinding (outcome assessors)	Incomplete outcome data addressed?	Free of selective reporting?
Aiken LS 2006 (20)	✓	✓	✗	✓	✗	✓
Bekelman DB 2015 (21)	✓	✓	✗	✓	✓	✓
Brännström M 2014 (22)	✓	✓	✗	✗	◇	✓
Hopp FP 2016 (23)	◇	◇	✗	✗	✓	✗
Rogers JG 2017 (24)	✓	◇	✗	✗	✓	✓
Sahlen KG 2015 (25)	✓	✓	✗	✗	✓	✓
Sidebottom AC 2015 (26)	◇	◇	✗	✗	✓	✓
Wong FKY 2016 (27)	✓	✓	✗	✓	✓	✓
Paes P 2005* (28)	✓	✗	✗	✗	✗	✓
Bakitas M 2017 (290)	N/A	N/A	✗	✗	✓	✓
Tadwalkar R 2014 (32)	N/A	N/A	✗	✗	◇	✓
O'Donnell A 2018 (30)	✓	◇	✗	◇	✓	✓

* Derived from the full thesis on which the letter was based and not from the limited information in the published letter.

N/A = not applicable

Key: ✓ = low risk of bias, ✗ = high risk of bias, ◇ = risk of bias unclear

Supplementary table 5: Results of NOS risk of bias assessment for cohort studies

Study	Representativeness of exposed cohort	Selection of non-exposed cohort	Ascertainment of exposure	Outcome of interest not present at start of study	Comparability of cohorts	Assessment of outcome	Length of follow up	Adequacy of follow up
Connor SR 2007 (33)	★	★	★	★	★	★	★	★
Enguidanos SM 2005 (34)	★	★	★	★	★	★	★	★
Pattenden JF 2013 (35)	★	★	★	★	★	★	★	★
Evangelista LS 2014† (36)	★	★	★	★	★	★	★	★
Evangelista LS 2014* (37)	★	★	★	★	★	★	★	★
Taylor GJ 2017 (38)	★	★	★	★	★	★	★	★
Wong RC 2013 (39)	★	★	★	★	★	★	★	★
Johnson MJ 2018* (31)	★	★	★	★	★	★	★	★

Key: ★ = low risk of bias, ★ = high risk of bias, ★ = risk of bias unclear

* Designed as a nonrandomised feasibility study rather than to examine outcomes, but methods more suited to quality appraisal as observational data.

Supplementary table 6: Results of NOS risk of bias assessment for case-control studies

Study	Adequate case definition	Representativeness of cases	Selection of controls	Definition of controls	Comparability of cases and controls	Ascertainment of exposure	Same method of ascertainment for cases and controls	Non-response rate
Cassel JB 2016 (40)	★	★	★	★	★	★	★	★
Evangelista LS 2012 (41)	★	★	★	★	★	★	★	★

Key: ★ = low risk of bias, ★ = high risk of bias, ★ = risk of bias unclear